Alpha-synuclein-targeted PROTACs also demonstrated benefits in models of Parkinson’s disease, with the latter promoting the degradation of pathogenic forms of alpha-synuclein while sparing the native form [152]. The gene discussed is SNCA; the disease is Parkinson disease.